Search clinical trials for: Alkotinib

Total 484 results

Henan Cancer Hospital

Recruiting

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

SCLC, Extensive Stage

China
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Qilu Hospital of Shandong University

Not yet recruiting

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Breast Cancer
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
Henan Cancer Hospital

Completed

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Soft Tissue Sarcomas

China
Gang Wu

Not yet recruiting

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Carcinoma, Non-Small Cell Lung
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Endometrial Cancer

China
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Second Affiliated Hospital of Nanchang University

Unknown

Phase I Study of the Combination of Anlotinib With Gefitinib

Non-squamous Non-small Cell Lung Cancer
Sun Yat-sen University

Not yet recruiting

Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Non Small Cell Lung Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Shanghai Chest Hospital

Completed

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Non Small Cell Lung Cancer

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
Zhongnan Hospital

Recruiting

Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer

Uterine Cervical Neoplasms | Angiogenesis | Chemoradiotherapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

MGMT-Unmethylated Glioblastoma

China
Shanghai Chest Hospital

Active, not recruiting

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Extensive-Stage Small-Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Lung Cancer | Lung Cancer Metastatic

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma (TAXE-GC)

Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zai Lab (Shanghai) Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (CC-ANNIE)

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

China
Hunan Province Tumor Hospital

Recruiting

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU)

Non Small Cell Lung Cancer | ALK Gene Mutation | MET Gene Mutation | EGFR Gene Mutation | ROS1 Gene Mutation

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
Fudan University

Not yet recruiting

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma (ALTER-UC-001)

Renal Cell Carcinoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Pancreatic Cancer | Gastric Adenocarcinoma | Cholangiocarcinoma | HER2-negative Breast Cancer

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
Henan Cancer Hospital
Cttq

Unknown

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Advanced Solid Tumor

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaborators

Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (ALTER-L024)

Non-small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Xijing Hospital

Not yet recruiting

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Melanoma

China
University Medical Center Groningen
Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation

Netherlands, France
Fudan University

Recruiting

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Metastatic Colorectal Cancer

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors

United States, Korea, Republic of, China, Spain, Canada, Australia, United Kingdom, Denmark, France, Italy, Germany, Brazil
Jihong Liu

Unknown

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer (ANNIE)

Platinum-resistant Ovarian Cancer

China
Sun Yat-sen University

Unknown

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Lung Cancer, Nonsmall Cell

China
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Chondrosarcoma

China
Shanghai Chest Hospital
Bristol-Myers Squibb

Completed

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

NSCLC Stage IV | Checkpoint Inhibitor

China
The Affiliated Hospital of Qingdao University

Completed

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NSCLC | Angiogenesis | Immunotherapy

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (OASIS)

Gastric Adenocarcinoma | Esophageal Squamous Cell Carcinoma
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer

Search clinical trials for: Alkotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations